Utilizzo di nivolumab da solo o con cabozantinib per prevenire il ritorno del melanoma della mucosa dopo l'intervento chirurgico
Uno studio randomizzato di fase II sull'adiuvante nivolumab con o senza cabozantinib in pazienti con melanoma della mucosa resecato
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving nivolumab in combination with cabozantinib could prevent cancer from returning.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
- Melanoma della mucosa
- Melanoma anale
- Melanoma vescicale
- Melanoma cervicale
- Melanoma esofageo
- Melanoma della cistifellea
- Melanoma della mucosa del cavo orale
- Melanoma della mucosa del pene
- Melanoma rettale
- Melanoma mucoso ricorrente
- Melanoma della mucosa sinonasale
- Melanoma uretrale
- Melanoma vaginale
- Melanoma vulvare
- Melanoma per mucosa della testa e del collo
- Melanoma di mucosa rinofaringea
- Melanoma della mucosa del sistema urinario
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVE:
I. To compare the efficacy of adjuvant nivolumab (480 mg every [q]4 weeks) versus nivolumab plus cabozantinib s-malate (cabozantinib) (40 mg daily) in patients with mucosal melanoma.
SECONDARY OBJECTIVES:
I. To compare overall survival between the two adjuvant therapies. II. To evaluate the adverse effects in each arm. III. To assess the correlation between PD-L1 expression in tumor cells with survival (recurrence free survival [RFS] and overall survival [OS]).
IV. To evaluate the overall response rate (ORR), duration of response (DOR), progression free survival (PFS), and OS of nivolumab plus cabozantinib in patients who cannot undergo gross total resection of disease or have metastatic disease at baseline.
V. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.
OUTLINE: Patients whose tumor has been fully removed by surgery are randomized to Arm 1 or Arm 2. Patients whose tumor has not been fully removed by surgery or has spread are assigned to Arm 3.
ARM 1: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 and cabozantinib orally (PO) once daily (QD) of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
ARM 2: Patients receive nivolumab IV over 30 minutes on day 1 and placebo PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
ARM 3: Patients receive nivolumab IV over 30 minutes and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo echocardiogram (ECHO) during screening and as clinically indicated throughout the trial. Patients may undergo computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial.
After completion of study treatment, patients are followed up every 3 months until disease progression, and then every 6 months for up to 5 years from registration or until death.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Ottawa Hospital and Cancer Center-General Campus
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Canada, M4N 3M5
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Jewish General Hospital
-
-
-
-
California
-
Auburn, California, Stati Uniti, 95602
- Sutter Auburn Faith Hospital
-
Berkeley, California, Stati Uniti, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Fremont, California, Stati Uniti, 94538
- Palo Alto Medical Foundation-Fremont
-
Los Angeles, California, Stati Uniti, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Stati Uniti, 90020
- Keck Medicine of USC Koreatown
-
Los Angeles, California, Stati Uniti, 90033
- Los Angeles General Medical Center
-
Modesto, California, Stati Uniti, 95355
- Memorial Medical Center
-
Newport Beach, California, Stati Uniti, 92663
- USC Norris Oncology/Hematology-Newport Beach
-
Palo Alto, California, Stati Uniti, 94304
- Stanford Cancer Institute Palo Alto
-
Palo Alto, California, Stati Uniti, 94301
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Stati Uniti, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Stati Uniti, 95816
- Sutter Medical Center Sacramento
-
San Francisco, California, Stati Uniti, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Stati Uniti, 94115
- California Pacific Medical Center-Pacific Campus
-
San Mateo, California, Stati Uniti, 94401
- Mills Health Center
-
Santa Cruz, California, Stati Uniti, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Stati Uniti, 95403
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Stati Uniti, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Stati Uniti, 94589
- Sutter Solano Medical Center/Cancer Center
-
-
Colorado
-
Englewood, Colorado, Stati Uniti, 80113
- The Melanoma and Skin Cancer Institute
-
-
Florida
-
Aventura, Florida, Stati Uniti, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Stati Uniti, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Stati Uniti, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Stati Uniti, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Plantation, Florida, Stati Uniti, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Caldwell, Idaho, Stati Uniti, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Stati Uniti, 83814
- Kootenai Health - Coeur d'Alene
-
Nampa, Idaho, Stati Uniti, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Post Falls, Idaho, Stati Uniti, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Stati Uniti, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Aurora, Illinois, Stati Uniti, 60504
- Rush-Copley Medical Center
-
Centralia, Illinois, Stati Uniti, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern University
-
Danville, Illinois, Stati Uniti, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Stati Uniti, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Stati Uniti, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Stati Uniti, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Stati Uniti, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Stati Uniti, 62401
- Carle Physician Group-Effingham
-
Geneva, Illinois, Stati Uniti, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Stati Uniti, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Stati Uniti, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Lake Forest, Illinois, Stati Uniti, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Stati Uniti, 61938
- Carle Physician Group-Mattoon/Charleston
-
O'Fallon, Illinois, Stati Uniti, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Stati Uniti, 60462
- Northwestern Medicine Orland Park
-
Springfield, Illinois, Stati Uniti, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Stati Uniti, 62702
- Springfield Clinic
-
Springfield, Illinois, Stati Uniti, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Stati Uniti, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Stati Uniti, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Yorkville, Illinois, Stati Uniti, 60560
- Rush-Copley Healthcare Center
-
-
Iowa
-
Ames, Iowa, Stati Uniti, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Stati Uniti, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Stati Uniti, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Boone, Iowa, Stati Uniti, 50036
- McFarland Clinic - Boone
-
Clive, Iowa, Stati Uniti, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Stati Uniti, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stati Uniti, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Stati Uniti, 50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson, Iowa, Stati Uniti, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Stati Uniti, 50158
- McFarland Clinic - Marshalltown
-
Waukee, Iowa, Stati Uniti, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Battle Creek, Michigan, Stati Uniti, 49017
- Bronson Battle Creek
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Stati Uniti, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Stati Uniti, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Stati Uniti, 49009
- Beacon Kalamazoo Cancer Center
-
Muskegon, Michigan, Stati Uniti, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Stati Uniti, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Stati Uniti, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Stati Uniti, 49677
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Stati Uniti, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Traverse City, Michigan, Stati Uniti, 49684
- Munson Medical Center
-
Wyoming, Michigan, Stati Uniti, 49519
- University of Michigan Health - West
-
-
Minnesota
-
Burnsville, Minnesota, Stati Uniti, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Stati Uniti, 55433
- Mercy Hospital
-
Edina, Minnesota, Stati Uniti, 55435
- Fairview Southdale Hospital
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Abbott-Northwestern Hospital
-
Robbinsdale, Minnesota, Stati Uniti, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, Stati Uniti, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Stati Uniti, 55102
- United Hospital
-
-
Missouri
-
Farmington, Missouri, Stati Uniti, 63640
- Parkland Health Center - Farmington
-
Sainte Genevieve, Missouri, Stati Uniti, 63670
- Sainte Genevieve County Memorial Hospital
-
St Louis, Missouri, Stati Uniti, 63131
- Missouri Baptist Medical Center
-
Sullivan, Missouri, Stati Uniti, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Anaconda, Montana, Stati Uniti, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Stati Uniti, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Stati Uniti, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Stati Uniti, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Stati Uniti, 59901
- Logan Health Medical Center
-
Missoula, Montana, Stati Uniti, 59804
- Community Medical Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Stati Uniti, 07920
- Memorial Sloan Kettering Basking Ridge
-
-
New York
-
Camillus, New York, Stati Uniti, 13031
- Hematology Oncology Associates of CNY at Camillus
-
East Syracuse, New York, Stati Uniti, 13057
- Hematology Oncology Associates of Central New York-East Syracuse
-
Harrison, New York, Stati Uniti, 10604
- Memorial Sloan Kettering Westchester
-
Lake Success, New York, Stati Uniti, 11042
- Northwell Health/Center for Advanced Medicine
-
Mineola, New York, Stati Uniti, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Stati Uniti, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
Ohio
-
Centerville, Ohio, Stati Uniti, 45459
- Miami Valley Hospital South
-
Cincinnati, Ohio, Stati Uniti, 45220
- Good Samaritan Hospital - Cincinnati
-
Cleveland, Ohio, Stati Uniti, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Stati Uniti, 44109
- MetroHealth Medical Center
-
Dayton, Ohio, Stati Uniti, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Stati Uniti, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Stati Uniti, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Stati Uniti, 45409
- Premier Blood and Cancer Center
-
Franklin, Ohio, Stati Uniti, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Stati Uniti, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Stati Uniti, 45429
- Kettering Medical Center
-
Troy, Ohio, Stati Uniti, 45373
- Upper Valley Medical Center
-
-
Oklahoma
-
Lawton, Oklahoma, Stati Uniti, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Ontario, Oregon, Stati Uniti, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- UPMC Hillman Cancer Center
-
Willow Grove, Pennsylvania, Stati Uniti, 19090
- Asplundh Cancer Pavilion
-
-
South Dakota
-
Rapid City, South Dakota, Stati Uniti, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Stati Uniti, 57105
- Avera Cancer Institute
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- UT MD Anderson Cancer Center
-
-
Virginia
-
Richmond, Virginia, Stati Uniti, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Stati Uniti, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Wisconsin
-
Eau Claire, Wisconsin, Stati Uniti, 54701
- Marshfield Medical Center-EC Cancer Center
-
Eau Claire, Wisconsin, Stati Uniti, 54701
- HSHS Sacred Heart Hospital
-
Green Bay, Wisconsin, Stati Uniti, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, Stati Uniti, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Madison, Wisconsin, Stati Uniti, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Stati Uniti, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Stati Uniti, 54548
- Marshfield Medical Center - Minocqua
-
Oconto Falls, Wisconsin, Stati Uniti, 54154
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Rice Lake, Wisconsin, Stati Uniti, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Stati Uniti, 53081
- Saint Vincent Hospital Cancer Center at Sheboygan
-
Stevens Point, Wisconsin, Stati Uniti, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Sturgeon Bay, Wisconsin, Stati Uniti, 54235-1495
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Weston, Wisconsin, Stati Uniti, 54476
- Marshfield Medical Center - Weston
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
STEP 0 INCLUSION CRITERIA
-
Histologically proven mucosal melanoma by local pathology
-
Central PD-L1 tumor tissue submission
-
STEP 1 INCLUSION CRITERIA
-
Receipt of the central PD-L1 testing results available
- Report is required for randomization of resection R0 or R1 patients
- Testing must be started in Step 0 but results can be reported after registration for resection R2 patients
-
Disease status-Resected R0 or R1 disease patients. Patients eligible for randomization have resected R0 or R1 disease (with negative margins or positive microscopic margins) that must meet one of the following 4 criteria as defined below:
-
Regional lymph node (LN) involvement; OR
-
In-transit metastases/satellite primary disease; OR
-
Single localized, primary disease meeting one of the following site-specific requirements:
-
Head/neck - Sinonasal (including nasopharynx): any primary lesion; Nasal or oral cavity; pT4a or above, given slightly improved OS
- NOTE: Conjunctival: does not meet the qualification for eligibility
-
Anorectal - any primary lesion
-
Vaginal/cervical - any primary, as they have 5 year OS rates of 5-25%
-
Urinary tract - any primary urethral or bladder tumor
-
Penile
-
Vulvar- American Joint Committee on Cancer (AJCC) cutaneous stage IIB or higher
-
Esophageal/gallbladder - any primary
-
-
Locoregionally recurrent following prior resection, meeting at least one of the above criteria
-
In addition, patients must have undergone cross-sectional imaging of the brain, chest, abdomen and pelvis with no evidence of distant metastatic disease
-
-
Disease status-Non-resected R2 or metastatic disease patients
- Non-resected R2 or metastatic disease that is assessable and measurable radiographically or by physical examination
-
Prior Treatment:
- No prior systemic checkpoint inhibitor therapy of mucosal melanoma, including in the adjuvant setting, is allowed. Prior adjuvant chemotherapy or interferon is allowed.
- No other active, concurrent malignancy that requires ongoing systemic treatment or interferes with radiographic assessment of melanoma response as determined by the investigator. Exceptions may allow for adjuvant no evidence of disease (NED) cancers undergoing hormone based therapy may be eligible pending the other eligibility criteria are met and the principal investigator (PI) affirms the hormonal agent would not change the melanoma response.
- Any radiation must have completed 28 days prior to randomization and the patient must have adequately recovered from its effects.
- For resectable patients only: Surgery must have completed 28 days prior to randomization.
- For resectable patients only: Surgery must have completed no more than 84 days prior to randomization.
-
Not pregnant and not nursing, because this study has an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
-
Absolute neutrophil count (ANC) >= 1,500/mm^3
-
Platelet count >= 100,000/mm^3
-
Creatinine =< 1.5 x upper limit of normal (ULN) OR creatinine clearance (CrCl) >= 50mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
-
Albumin >= 2.8 g/dL
-
Total bilirubin =< 1.5 x upper limit of normal (ULN)
-
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
-
No cardiovascular disease, including:
- No history of acute coronary syndromes (including myocardial infarction and unstable angina), coronary artery bypass graft (CABG) coronary angioplasty, or stenting within 6 months prior to study entry.
- No history of current class II or higher congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system.
- No refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg despite adequate attempts at anti-hypertensive therapy.
- No history of myocarditis.
- No history of syncope of cardiovascular etiology, uncontrolled cardiac arrhythmia, history of Mobitz II second degree or third degree heart block without a permanent pacemaker in Association (NYHA) class II to IV heart failure, or stroke/transient ischemic attack (TIA) within the past 3 months.
- No corrected QT interval by Fridericia's formula (QTcF) > 500 msec. Note: if initial QTcF is found to be > 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is =< 500 ms, the subject meets eligibility in this regard.
-
No underlying hematologic issues, including:
- Congenital bleeding diathesis
- Gastrointestinal (GI) bleeding requiring intervention within the past 6 months, unless directly related to mucosal melanoma
- Active hemoptysis within 42 days prior to study enrollment.
- Active tumor lesions with cavitations or tumor lesions which invade, encase, or abut major blood vessels. The anatomic location and characteristics of primary tumors or metastases as well as the medical history should be carefully reviewed in the selection of subjects for treatment with cabozantinib/placebo.
- Pulmonary emboli or deep vein thromboses (DVT) that require an active anticoagulation regimen.
- No known or suspected history of cytopenia (low white blood cell [WBC], hemoglobin or platelet count) of greater than 3 months duration with an unknown cause, myelodysplastic syndrome, or hematologic malignancies.
-
No clinical, laboratory or radiographic evidence of an active bacterial, fungal, or viral infection requiring treatment at the time of pre-registration (e.g., active symptoms of COVID-19 infection or a post-infectious symptomatic autoimmune syndrome, serious bacterial infections requiring antibiotics).
-
No known or suspected gastrointestinal disorder affecting absorption of oral medications.
-
Comorbid conditions:
-
No active autoimmune disease or any condition requiring systemic treatment with either corticosteroids (> 10 mg daily of prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
-
No history of autoimmune motor neuropathy (e.g., Guillain-Barre syndrome, myasthenia gravis) or non-infectious pneumonitis.
-
No history of severe allergic reactions to an unknown allergen or any components of the study drugs or its excipients.
-
No history of gastrointestinal perforation or abdominal fistula.
-
No clinically suspected central nervous system (CNS) (leptomeningeal or parenchymal) metastases. Patients with a history of CNS metastasis(s) will be allowed as long as
- The metastatic site(s) were adequately treated as demonstrated by clinical and radiographic improvement, AND
- The patient has recovered from the intervention (no residual adverse events > Common Terminology Criteria for Adverse Events [CTCAE] grade 1), AND
- The patient has remained without occurrence of new or worsening CNS symptoms for a period of 28 days prior to enrollment.
-
No history of seizure or any condition that may increase the patient's seizure risk (e.g., prior cortical stroke, significant brain trauma) within 2 years.
-
No clinically active or chronic liver disease resulting in moderate/severe hepatic impairment (Child-Pugh class B or C), ascites, coagulopathy or bleeding due to liver dysfunction.
-
No untreated spinal cord compression or evidence of spinal metastases with a risk of impending fracture or spinal cord compression. Spinal metastases must have completed planned radiation or surgical therapy prior to registration.
-
-
Concomitant medications:
- Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug for 5 days prior to the start of study treatment.
- Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 5 days prior to the start of study treatment.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Arm 1 (nivolumab, cabozantinib)
Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial. |
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Given PO
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo PET
Altri nomi:
Given IV
Altri nomi:
Undergo bone scan
Altri nomi:
Undergo blood and tissue sample collection
Altri nomi:
|
|
Comparatore attivo: Arm 2 (nivolumab, placebo)
Patients receive nivolumab IV over 30 minutes on day 1 and placebo PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial. |
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo PET
Altri nomi:
Given IV
Altri nomi:
Undergo bone scan
Altri nomi:
Undergo blood and tissue sample collection
Altri nomi:
Given PO |
|
Sperimentale: Arm 3 (nivolumab, cabozantinib)
Patients receive nivolumab IV over 30 minutes and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial. |
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Given PO
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo PET
Altri nomi:
Given IV
Altri nomi:
Undergo bone scan
Altri nomi:
Undergo blood and tissue sample collection
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Recurrence free survival (RFS)
Lasso di tempo: Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
Will evaluate RFS of single agent adjuvant nivolumab plus placebo compared to the combination treatment of adjuvant nivolumab plus cabozantinib in patients with resected mucosal melanoma. |
Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall survival (OS)
Lasso di tempo: Number of days from registration until death (due to any cause, assessed up to 5 years
|
Will be evaluated utilizing the Kaplan-Meier (KM) method and, when appropriate, cox proportional hazards models. Median OS is calculated (along with 95% Confidence intervals) using the KM method. A Cox proportional hazards model is built to compare arms 1 and 2 with respect to OS. |
Number of days from registration until death (due to any cause, assessed up to 5 years
|
|
RFS
Lasso di tempo: Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
Median RFS will be calculated (along with 95% Confidence intervals) using the KM method. A Cox proportional hazards model will also be built to compare arms 1 and 2 with respect to RFS, with and without stratifying for PD-L1 categorization. For non-resected cohort, If a patient in this group has surgery, their RFS data will be censored at the time of surgery. |
Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
|
Progression free survival
Lasso di tempo: Number of days from registration until either radiographic or clinical progression or death (due to any cause), assessed up to 5 years
|
Will be evaluated in multiple settings utilizing the KM method and, when appropriate, cox proportional hazards models. |
Number of days from registration until either radiographic or clinical progression or death (due to any cause), assessed up to 5 years
|
|
Objective response rate (Arm 3)
Lasso di tempo: Up to 5 years
|
Will assess this endpoint utilizing a two-stage Simon that looks to improve from a rate of 20% to 47%. |
Up to 5 years
|
|
Duration of response (Arm 3)
Lasso di tempo: Time from the first evidence of response until progression, assessed up to 5 years
|
A KM analysis is performed to calculate the median duration of response and 95% confidence intervals are constructed. |
Time from the first evidence of response until progression, assessed up to 5 years
|
|
Incidence of adverse events
Lasso di tempo: Up to 5 years
|
The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be summarized. |
Up to 5 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Alexander N Shoushtari, Alliance for Clinical Trials in Oncology
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Aminoacidi, peptidi e proteine
- Proteine
- Tecniche investigative
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Nivolumab
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- Cabozantinib
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NCI-2021-11794
- U10CA180821 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2021-11794 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- A091903 (Altro identificatore: CTEP)
- A091903 (Altro identificatore: Alliance for Clinical Trials in Oncology)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .